Buyers we built this for.
Government capital intelligence applies broadly. It lands differently depending on what you do all day. Below, how the platform fits across distinct buyer profiles, what you'd actually use it for, and who shouldn't sign up. If you haven't read the overview, start there for the category. This page assumes you already get the basics.
Deal flow that arrives 6 to 18 months before the headlines.
Most VCs source the same way. Founder networks, accelerator demo days, warm intros from portfolio companies, the occasional Twitter find. By the time a deal lands in your inbox, the company has raised seed, picked their lead, and priced their A. The signal you needed, that this sector was about to receive eight figures of government capital, was public for months. It just wasn't in your reading flow.
Even when you do see government signals, you can't tell which ones matter. A White House strategy document reads the same as a UKRI grant call reads the same as a sovereign wealth co-investment unless you can place each in its 6-to-18 month deployment cycle and score the follow-through probability. Most funds default to ignoring the entire layer. Funds that build the discipline to read it get a structural source of edge that competitors can't easily replicate.
Professional tier covers all 16 markets and is the right starting point for most VC funds. The Capital Velocity Index gives you a single daily number per sector, telling you whether government deployment is accelerating or decelerating in your investment areas. The Decision Matrix tells you whether a specific signal warrants action this week or this quarter. Compliance Brief flags regulatory shifts that affect portfolio companies. Constellation Briefing surfaces multi-agency convergence, those moments when three or four federal agencies start coordinating on the same capability area, which tends to precede founder-formation cycles by 6 to 12 months.
For funds that need pattern recognition across sectors and markets, Growth tier adds Regulatory Cascade, Cross-Sector Spillover, and Analogical Intelligence. The cascade product predicts how a regulatory action in one market reshapes the next. The spillover product detects when activity in one sector creates downstream effects in others.
Take a typical DoD AI pre-solicitation. The platform's calibration data shows 87% historical follow-through to a public award, median $40M ceiling, 8-month median time-to-outcome, and roughly two dozen likely bidders. Three prior calls in the same programme family have already been awarded. From the moment of publication, the platform shows you which incumbents won prior calls, what the historical capture rate is for new entrants, and which adjacent sectors typically see spillover funding within 12 to 18 months.
For a fund running concentrated theses, three signals like this per quarter are the difference between sourcing the breakout company and reading about it later in someone else's portfolio announcement. Across 16 markets, 24 sectors, and 6 signal types, the daily pipeline surfaces 200 to 500 of these.
This isn't for solo angels investing under $250K per ticket. It isn't for generalist seed funds with no sector concentration. And it isn't for any fund whose investment thesis doesn't depend on government policy or capital deployment timing. If your sourcing is warm intros and that works, the platform is more than you'd use day to day. If your LP mandate is consumer software, government capital signals are noise to you. Charter access opens later in 2026 if you want to test the platform before committing.
Strategic moves before your competitors see them coming.
If you're running corporate strategy or corp dev at a company in a regulated industry, government decisions move your industry more than any private-sector dynamic. Semiconductor sovereignty rules, energy procurement strategies, defense supply chain policy, advanced manufacturing subsidies. A single export-control update redraws supply chain assumptions overnight. The information itself is public. The problem is that it's scattered across hundreds of portals, written in dense regulatory prose, and arrives without prioritization.
A team of three corporate strategists can read maybe 5% of what's published in their sector each month. The other 95% gets summarized by industry newsletters with a 4-to-12 week lag. By then, competitors with better intelligence have already moved.
Growth tier is the standard starting point. All 16 markets, two seats (typically one strategy lead and one analyst), the full intelligence stack. Cross-Sector Spillover is built specifically for this buyer. It surfaces when government activity in one sector creates downstream effects in adjacent ones, which is the most common form of strategic signal corporate development teams need to track. Budget Trajectory shows multi-year government spending curves per sector, useful for capital allocation discussions with the CFO.
Enterprise tier adds Constellation Briefing for multi-agency alignment, Investment Thesis for directional assessment with kill criteria, and SEC EDGAR cross-reference. The last matters if your company is publicly listed and you need to coordinate strategic moves with disclosure obligations.
Take an export-control update on a critical input. A rare earth element, a specialty chemical, a regulated semiconductor component. The platform's calibration data shows what typically follows. Within 30 to 90 days, downstream procurement records reflect supplier diversification: incumbent contracts get renegotiated, new domestic suppliers appear in award databases, congressional appropriations sometimes follow. Within 180 days, sector-adjacent procurement tends to mirror the same pattern, because when one critical input is restricted, second-order substitutes face similar scrutiny.
The platform surfaces the original control update on day one. The procurement cascade gets tracked as it appears. The cross-sector spillover gets flagged as it forms, typically 4 to 6 weeks before industry coverage catches up.
That's one signal class out of 35 cross-cutting intelligence themes. Each one (supply chain resilience, critical minerals, semiconductor sovereignty, infrastructure megaprojects, foreign investment screening) has its own equivalent.
This isn't for M&A boutiques without a sector specialization. It isn't for generalist consultancies running quarterly trend reports. It isn't for in-house teams whose mandate is purely deal execution rather than strategic intelligence. If you're advising on transactions but not researching market structure, the platform is more depth than you'd use. If your industry is consumer-facing (retail, hospitality, entertainment), government capital signals matter less to your strategy than other inputs.
FDA, EMA, and procurement in one feed.
Life sciences companies operate in the most regulated capital environment in the world. A single FDA pathway change rearranges five years of product roadmap. An EMA scientific advice opinion shifts the design of every active trial. A CMS reimbursement decision determines whether a Phase 3 success becomes a viable product or a write-down. Most life sciences companies track these signals, but they track them in silos. Clinical affairs reads ClinicalTrials.gov. Regulatory affairs watches the FDA. Market access monitors CMS. Corporate development reads industry newsletters two weeks late. Cross-correlation between these streams happens in human heads, slowly, and with whatever bandwidth analysts have left after their primary jobs.
The harder problem is timing. FDA approvals don't generate procurement immediately. They generate it in a predictable cascade across the VA, DoD, NHS, Medicare, and major hospital systems over the 4-to-18 months that follow. Companies that anticipate the cascade win contracts. Companies that wait for it to be announced lose them. The intelligence sits in the same agency databases everyone has access to. The structural difference is whether you read it as a stream or as a system.
Growth tier covers most clinical and regulatory affairs needs. All 16 markets, full taxonomy, daily ingest, Compliance Brief filtering for regulatory directionality. For corporate development and market access teams, Enterprise tier adds the FDA-specific intelligence stack. FDA Approval Cascade tells you which follow-on agencies open procurement, when, and at what conversion rates. FDA Trial Trajectory traces Phase 2 to Phase 3 to approval to procurement timelines. FDA Generic Impact tracks ANDA approvals, branded revenue impact, and generic opportunity.
Cross-correlation across SEC filings, lobbying disclosures, and clinical trial registrations is built into the Enterprise stack. For publicly listed companies with disclosure obligations, that integration matters more than a separate research subscription would.
Take a typical 510(k) clearance for a new diagnostic platform. The platform's calibration data shows what follows. The VA opens procurement within 4 to 8 months in the majority of cases, with median capital meaningful at the platform tier. DoD follow-on within 6 to 12 months at high conversion rates. NHS adoption within 8 to 14 months at moderate conversion. The platform surfaces the original 510(k) the day it posts. Each downstream procurement signal gets tracked as it forms, linked back to the original FDA event.
For a corporate strategy team at a public medtech company, this isn't a single signal. It's a 14-month roadmap of competitor positioning, partnership opportunities, and disclosed pipeline benchmarks.
That's one cascade pattern out of dozens. Pharma generic impact, drug shortage triggers, CMS coverage decisions, EMA scientific advice patterns. Each has its own calibrated cascade structure.
This isn't for retail-facing health or wellness brands. It isn't for consumer health companies without regulated products. It isn't for pure CRO operators tracking only their own trials. If your business model doesn't depend on cross-correlating regulatory events with downstream procurement, the platform's intelligence stack is overbuilt for your use. Generic-only manufacturers tracking only ANDA filings can use the Compliance Brief layer in Professional or Growth tier. The full cascade architecture is for companies competing across regulatory and procurement timelines simultaneously.
Government signals, public-market positioning, in one feed.
If you run a long-short hedge fund with public-equity exposure to government-correlated sectors (defense primes, regulated pharma, semis, infrastructure), you already track government signals as part of your investment process. Your analysts pull from FDA, SEC, congressional hearings, agency budget documents, industry newsletters. The work is real. It's also slow, expensive, and inconsistent across analysts. One person tracks the FDA closely. Another reads the appropriations bills. A third watches DoD procurement. Cross-correlation between their inputs is whatever shows up in Monday morning meetings.
The structural problem is harder. Government signals don't naturally arrive in a form that maps to your positioning workflow. A DoD pre-solicitation is rarely a clean buy or sell signal on its own. It's an event that, in combination with eight other events, should update your conviction on a specific public name. The platform does that combination work today inside human heads, slowly and unevenly.
Enterprise tier is built for this buyer. SEC EDGAR cross-reference is the anchor. 13F positioning data, S-1 filings, and 10-K backlog disclosures get linked directly to the underlying procurement and regulatory signals. Your analysts can ask "which of our holdings have unusual government exposure right now" and get an answer in one query rather than ten. FDA Approval Cascade and FDA Trial Trajectory are critical for life-sciences-focused funds.
Family offices typically run a smaller number of seats and want broader coverage rather than deeper analytics. Growth tier often fits better.
Take a typical SEC 8-K cross-match with a government contract award. The platform's calibration data shows that when a publicly listed defense contractor files an 8-K disclosing a contract award, in the majority of cases that contract was preceded by a public pre-solicitation 8 to 14 months earlier. The platform surfaced the eventual disclosure to subscribed customers months before the filing date.
For a long-only fund with a 2-year holding period, this is information edge measured in months. For a long-short fund running 90-day positioning windows, it's information edge measured in days, depending on how you trade around the disclosure. The platform tracks hundreds of SEC filing patterns linked to government signal patterns, refreshed daily.
This isn't for retail-facing platforms. It isn't for robo-advisors or generalist asset managers without sector concentration. It isn't for any fund whose investment thesis doesn't depend on regulatory and procurement timing. If your portfolio is broad-market index exposure plus thematic ETFs, government capital signals are too granular to be actionable. If you trade on technicals or short-term momentum, the platform's 6-to-18 month signal lead times are longer than your holding periods.
From multilateral approval to contract award, in one feed.
Infrastructure investing is the most government-dependent asset class outside of defence. The pipeline is government-built. A toll road, a fiber backbone, a grid upgrade exists because a government decided to fund it, regulate it, or structure a concession around it. The IIJA, EU NextGenerationEU, multilateral development bank pipelines, Australia's Infrastructure Australia priority list, India's Gati Shakti. These programmes are the source of your dealflow.
You already track this. The problem isn't awareness. It's that the existing tools are fragmented and slow. Country-specific consultancies cover one market at a time. Established databases focus on the post-RFP stage of a deal, by which point the strategic positioning has happened. Multilateral pipelines, national budget allocations, regulatory rate decisions, and concession term changes sit in separate streams that don't naturally cross-correlate. A team of three analysts at an infrastructure fund tracking all of this manually is the standard configuration. It's also the most expensive part of the operating budget that doesn't scale.
Enterprise tier is the standard fit for infrastructure investors. Coverage spans all 16 markets and the full intelligence stack. Infrastructure Capital is the anchor product: World Bank, ADB, EBRD, EIB, EU Recovery, US federal programmes. Multilateral approvals, national budget allocations, and downstream procurement records get linked across the chain. Cross-Sector Spillover surfaces when activity in adjacent sectors (energy regulation, transport policy, environmental review) creates ripple effects on infrastructure programmes you're tracking. Constellation Briefing flags multi-agency alignment, the moments when a transport ministry, a development bank, and a regulatory body start coordinating on the same corridor or asset class.
For the largest funds operating across all major markets with embedded country desks, Government tier provides bespoke ingestion of priority markets, custom counterpart tracking, and white-label outputs for internal briefings.
Take a typical multilateral development bank board approval. The platform's calibration data shows the standard cascade. Within 6 to 12 months, the relevant national government typically signs the implementation agreement and incorporates the project into its public investment programme. Within 12 to 18 months, procurement frameworks get drafted and pre-qualification notices appear. Within 18 to 30 months, the actual contract awards follow, often to a small number of incumbent operators with regional track records.
The platform surfaces the original board approval the day it posts. Each downstream procurement signal gets tracked as it forms, linked back to the original board decision. For a fund evaluating an asset, the chain provides the underwriting context: who else has been awarded similar concessions in this market, what the historical conversion rate is from approval to award, where the regulatory inflection points sit in the timeline.
That's one cascade pattern. Energy transition programmes, transport corridor funding, water and sanitation pipelines, digital infrastructure rollouts. Each has its own calibrated structure.
This isn't for pure secondary funds buying existing operating assets, where greenfield pipeline matters less than asset-level due diligence. It isn't for real estate funds, even ones that overlap on data centres or logistics. It isn't for direct lenders to operating infrastructure, where the credit work is a different exercise. It isn't for single-asset investors who only deploy in one market. The platform's cross-border, cross-stage architecture is built for funds operating across multiple markets and stages of the infrastructure capital lifecycle simultaneously.
Cross-border deployment, on your jurisdiction and your terms.
Sovereign-mandate buyers (national innovation agencies, trade promotion bodies, foreign investment offices, sovereign wealth research desks) operate in an awkward position. You see your own funding pipelines and your own jurisdiction clearly. What you see less clearly is what counterpart governments are doing in adjacent sectors, which markets are opening to your domestic firms, and how your deployment compares to peer programmes operating at the same maturity stage.
For trade promotion bodies in particular, the structural challenge is reverse-mapping. Your job is helping domestic firms compete in foreign markets and helping foreign capital invest at home. Both halves require reading another country's procurement signals, regulatory shifts, and policy direction the way an investor reads them. Most trade bodies do this with industry analysts, country desks, and consultancy reports. The intelligence is real, but it's slow, expensive, and rarely updates fast enough to brief a minister before a counterpart announcement breaks publicly.
Government tier is built for sovereign and trade deployment. Coverage spans all 16 markets at the depth you require, including bespoke ingestion of your specific jurisdiction and your priority counterpart markets. Custom market mapping captures the agencies, programmes, and counterparts most relevant to your portfolio strategy. Counterpart agency tracking surfaces what peer national bodies are funding or procuring, when, and at what scale. Political Transition Analysis models how upcoming election cycles in your jurisdiction or counterpart jurisdictions affect deployment programmes you depend on.
White-label intelligence outputs allow your team to integrate Svatantra-derived intelligence into internal briefings and ministerial reports without external attribution. SLA-backed deployment, dedicated support, and bespoke source coverage are part of the engagement.
Take a peer agency's flagship grant call. A quantum technology programme launched by a national research foundation in another market. The platform surfaces it the day it announces. Within days, you see the specific technology areas being prioritized, the budget commitment, the multi-stage structure, and the historical follow-through pattern of similar programmes from that agency. Within weeks, you see which adjacent agencies in the same market begin signalling alignment. That's a constellation pattern, and it suggests the programme is part of a broader strategic move rather than a standalone funding event.
For a trade body advising domestic firms on entry to that market, this is the structural intelligence that informs commercial guidance. For a national innovation agency thinking about its own portfolio mix, it's the comparator that informs strategic positioning conversations with ministers.
The platform tracks innovation agencies, sovereign wealth funds, multilateral development banks, and bilateral programmes globally.
This isn't for sub-national agencies without independent budgetary authority. It isn't for university technology transfer offices. It isn't for accelerator programmes operating in a single sector. The Government tier deployment makes sense for entities with sovereign mandate, multi-sector portfolios, and the operational capacity to absorb cross-border intelligence at scale. For smaller programmes, Growth or Enterprise tier provides relevant coverage without the bespoke deployment overhead.